All In Biotech

Drug Trial Radar · NCT06724640

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered Long-acting Formulations of VH4011499 in Adults Without HIV

Last checked: Nov 20, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Dec 16, 2024

Primary completion

Aug 16, 2028

Study completion Aug 16, 2028

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate safety, pharmacokinetics and tolerability following single ascending dose (SAD) and multiple ascending doses (MAD) of VH4011499 administered subcutaneously (SC) and intramuscularly (IM) in participants without HIV.

Conditions

  • HIV Infections

Interventions

  • VH4011499 low dose InjectionDrug

    VH4011499 low dose Injection will be administered subcutaneously and/or intramuscularly.

  • VH4011499 high dose InjectionDrug

    VH4011499 high dose Injection will be administered subcutaneously and/or intramuscularly.

  • PlaceboDrug

    Placebo Injection will be administered either subcutaneously or intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs), including Injection Site Reaction (ISR) AEs, as per severity of Grade 2-5 using the DAIDS grading scaleTime frame: Up to Week 78
  2. Area under the plasma-concentration time curve from time zero to infinity (AUC0-inf) of VH4011499 for SAD groupTime frame: Up to Week 78
  3. Area under the plasma concentration vs time curve (AUC0-tau) for MAD groupTime frame: Up to Week 78
  4. Maximum observed plasma concentration (Cmax) of VH4011499Time frame: Up to Week 78
  5. Time to maximum observed plasma concentration (tmax) of VH4011499Time frame: Up to Week 78
  6. Apparent terminal half-life (t1/2) of VH4011499Time frame: Up to Week 78

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Las Vegas, Nevada · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.